Palisade Bio
PALI
Market cap $3.85M

2.52 USD

-0.10

3.82%

At close Nov 15, 4:00 PM EST

1 day

-3.82%

5 days

-0.40%

1 month

-29.01%

3 months

-32.08%

6 months

-60.50%

Year to date

-70.97%

1 year

-68.30%

5 years

-99.97%

10 years

-99.97%

About: Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Employees: 9

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,704 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

62% more capital invested

Capital invested by funds: $136K [Q2] → $220K (+$84.5K) [Q3]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

14% more funds holding

Funds holding: 7 [Q2] → 8 (+1) [Q3]

2.05% more ownership

Funds ownership: 3.21% [Q2] → 5.26% (+2.05%) [Q3]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$8

217%

upside

Avg. target

$8

217%

upside

High target

$8

217%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Maxim Group

Naz Rahman

15% 1-year accuracy

2 / 13 met price target

217%upside

$8

Buy

Maintained

13 Nov 2024

See Analyst Rankings

Financial journalist opinion

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood. This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end

Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108

Palisade Bio Participates in Virtual Investor “What this Means” Segment

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients

Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate, PALI-2108

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative Colitis (UC) PALI-1908 is in development to treat patients with active fibro stenotic Crohn's Disease (CD) Carlsbad, CA, July 19, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that European Patent Office (EPO) has issued a decision to grant notice for patent number 4,157,853 titled, “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors.” Based on the intention to grant notice, the Company expects the EPO to issue a patent July 31, 2024.

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of moderate-to-severe ulcerative colitis (UC) before year end Carlsbad, CA, July 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the successful completion of the first Good Manufacturing Practice (GMP) batch of its drug substance PALI-2108, an orally administered, locally acting colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug in development for patients affected by UC. The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization.

Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET. As part of the event, J.D.

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

See News Rankings

Charts implemented using Lightweight Charts™